96 related articles for article (PubMed ID: 21076302)
1. Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer.
Zalcman G; Bergot E; Creveuil C; Levallet G; Lechapt E
Curr Opin Oncol; 2011 Jan; 23(1):106-11. PubMed ID: 21076302
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
[TBL] [Abstract][Full Text] [Related]
3. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.
Shepherd FA; Tsao MS
J Clin Oncol; 2010 Feb; 28(6):903-5. PubMed ID: 20100955
[No Abstract] [Full Text] [Related]
5. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
6. [The evaluation of prognostic value of cyclin B1 expression in patients with resected non-small-cell lung cancer stage I-IIIA--preliminary report].
Kosacka M; Korzeniewska A; Jankowska R
Pol Merkur Lekarski; 2010 Feb; 28(164):117-21. PubMed ID: 20369739
[TBL] [Abstract][Full Text] [Related]
7. New agents in advanced non-small-cell lung cancer treatment.
Ricciardi S; de Marinis F
Oncology; 2009; 77 Suppl 1():103-12. PubMed ID: 20130438
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers as prognostic factors in treated non-small cell lung cancer.
Trapé J; Buxo J; Pérez de Olaguer J; Vidal C
Anticancer Res; 2003; 23(5b):4277-81. PubMed ID: 14666638
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-receptor-related protein p29 in primary nonsmall cell lung carcinoma: pathologic and prognostic correlations.
Vargas SO; Leslie KO; Vacek PM; Socinski MA; Weaver DL
Cancer; 1998 Apr; 82(8):1495-500. PubMed ID: 9554526
[TBL] [Abstract][Full Text] [Related]
11. Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?
Boutros PC; Pintilie M; John T; Starmans MH; Der SD; Shepherd FA; Tsao MS; Jurisica I
J Natl Cancer Inst; 2010 Nov; 102(21):1677-8; author reply 1678-9. PubMed ID: 20921041
[No Abstract] [Full Text] [Related]
12. EGF receptor in lung cancer: a successful story of targeted therapy.
Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
[TBL] [Abstract][Full Text] [Related]
13. Trial watch: Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment.
Nat Rev Drug Discov; 2010 Jun; 9(6):423. PubMed ID: 20514061
[No Abstract] [Full Text] [Related]
14. ERCC1 measurements in clinical oncology.
Reed E
N Engl J Med; 2006 Sep; 355(10):1054-5. PubMed ID: 16957152
[No Abstract] [Full Text] [Related]
15. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer.
Ishikawa N; Daigo Y; Takano A; Taniwaki M; Kato T; Tanaka S; Yasui W; Takeshima Y; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
Cancer Sci; 2006 Aug; 97(8):737-45. PubMed ID: 16863507
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.
Au NH; Cheang M; Huntsman DG; Yorida E; Coldman A; Elliott WM; Bebb G; Flint J; English J; Gilks CB; Grimes HL
J Pathol; 2004 Sep; 204(1):101-9. PubMed ID: 15307143
[TBL] [Abstract][Full Text] [Related]
17. CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma.
Wang J; Yi Y; Li B; Wang Z; Sun H; Zhang P; Huang W
Biomarkers; 2010 Nov; 15(7):594-601. PubMed ID: 20649505
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine for non-small cell lung cancer.
Piccirillo MC; Daniele G; Di Maio M; Bryce J; De Feo G; Del Giudice A; Perrone F; Morabito A
Expert Opin Drug Saf; 2010 May; 9(3):493-510. PubMed ID: 20350282
[TBL] [Abstract][Full Text] [Related]
20. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
